Immuno Oncology Assays Market Size, Share, and Industry Analysis By Product (Instruments and Consumables), By Technology (Immunoassay, Polymerase Chain reaction (PCR), Next-generation sequencing (NGS), Flow Cytometry, and Others), By Cancer Type (Colorectal Cancer, Lung Cancer, Melanoma, and Others), By End User (Hospitals & Clinics, Academic and Research Institutes, and Others), and Regional Forecast till 2032

The global immuno oncology assays market is expanding as new methods to study immuno-oncology samples through mIHC, mIF, and flow cytometry technologies are enhancing research progress. Research and medical tests rely on immuno-oncology assays to investigate immune system and cancer cell relationships.

• According to ClinicalTrials.gov (U.S. National Library of Medicine), 28% of global oncology clinical trials focused on immuno-oncology in 2024.
• According to World Health Organization (WHO), an estimated of 19.3 million of new cancer cases were reported globally in 2020.

Biopsy methods that depend on tissue invasion have their effectiveness reduced by diversity in cancer cell patterns. By testing blood and other body fluids for ctDNA and CTCs plus other markers, liquid biopsies let doctors observe tumour growth patterns without invasion and at repeat intervals while tracking immune response changes.

Immuno Oncology Assays Market Driver

Increasing Prevalence of Cancer to Expand the Market

The number of cancer cases worldwide keeps growing and claims more lives than any other disease throughout the globe. Rising cancer cases generate a robust need for advanced methods to diagnose and treat cancer using immuno-oncology tests.

Government and Private Sector Funding to Advance the Market

Public and private organisations allocate large amounts to advance the immuno-oncology assays market. The National Institutes of Health leads United States cancer research by funding immuno-oncology analysis through federal government money.

Immuno Oncology Assays Market Restraint

High Cost of Immuno-Oncology Treatments and Assays to Pose Potential Impediments on this Market

Current immuno-oncology therapies show exceptional benefits in specific kinds of cancer, yet they cost a substantial amount. The high expense includes both tests for treating and monitoring patients with immuno-oncology drugs.

Immuno Oncology Assays Market Opportunity

Healthcare Industries of Emerging Countries to Create Opportunity in this Market

The healthcare industries of emerging countries offer growth potential for immuno-oncology test markets. The developed nations lead immuno-oncology research since other nations recognise these therapies and tests will help fight cancer.

Segmentation

Key Insights

The report covers the following key insights:

• Market drivers, restraints and opportunities
• Influence of key industrial players and key developments
• Healthcare expenditure
• Research and development

Analysis by product

By product, the immuno oncology assays market is divided into instruments and consumables.

Instruments encompasses the hardware essential for conducting immuno-oncology assays. Continuous research and development lead to the growth of this market.

The consumables part of the market includes all single-use products such as reagents and kits required during immuno-oncology tests. The strong market size of this segment comes from regular demand for products used up in tests.

Analysis by Technology

Based on technology, the market is divided into immunoassay, polymerase chain reaction (PCR), Next-generation sequencing (NGS), flow cytometry, and others.

Researchers heavily rely on immunoassay tests as they detect specific matches between antibody and antigen targets in immuno-oncology. The increased use of multiplex immunoassays helps healthcare professionals gain a better understanding of the tumour's surroundings during one test.

PCR-based tests are needed to study how genes change and find genetic changes that control immune response mechanisms. PCR-based technology growth happens because labs use the advanced qPCR scanning method more often to measure gene activity. The development of digital PCR (dPCR) for highly sensitive detection of genetic alterations.

Analysis by Cancer Type

Based on cancer type, the market is divided into colorectal cancer, lung cancer, melanoma, and others.

Scientists conduct vital research to design better treatments for colorectal cancer since it affects many patients worldwide. Immunology tests help doctors find patients who will experience the most benefit from treatment with checkpoint inhibitors. Medical professionals use tests to see how treatment works and find out when resistance appears.

New methods of treating NSCLC lung cancer patients through immunotherapy have brought about important progress. Cancer patients need specific tests at immuno-oncology to qualify for checkpoint inhibitor treatment. Measuring how well immunotherapies function together when used as treatment.

Analysis by End User

Based on end user, the market is divided into hospitals & clinics, academic & research institutes, and others.

Healthcare facilities that serve cancer patients need immuno-oncology tests as their main consumer group. Clinics' and hospitals' usage of immunotherapy increases their need for fast and dependable tests used in immuno-oncology. The segment may lead the market.

Designed for exploration, academic and research centres push immuno-oncology development forward through their scientific studies. The increased availability of funds for cancer research boosts the development of immuno-oncology projects at both academic and research facilities.

Regional Analysis

To gain extensive insights into the market, Download for Customization

Based on region, the immuno oncology assays market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America, and especially the U.S., has emerged first in immuno-oncology research and development. The region features well-established healthcare services plus significant cancer research funds combined with high numbers of cancer patients in the population. Leading pharmaceutical and biotech firms, plus top research centres, have sped up the creation of immuno-oncology testing methods in this region.

Europe becomes a large market for immuno-oncology assay testing because the ageing population is increasing while cancer rates and healthcare costs keep rising. Research facilities across this region remain prominent due to several well-known universities and science centres. European nations have established measures to help cancer research while making new treatment methods available to patients.

The immuno-oncology assays market in Asia Pacific grows fast due to its substantial population increase plus rising cancer patient numbers and expanding healthcare budgets. China Japan and South Korea spend significant money to build medical facilities and support medical discovery work. Personalised medicine treatments and better diagnostic methods become more popular as the region develops.

Key Players Covered

The report includes the profiles of the following key players:

• F. Hoffmann-La Roche Ltd (Switzerland)
• Laboratory Corporation of America Holdings (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)  
• BD (U.S.)
• Merck KGaA (Germany)
• Agilent Technologies, Inc. (U.S.)
• Illumina, Inc. (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)

Key Industry Developments

• In November 2023, Bristol Myers Squibb and Immatics launched their joint effort to create T-cell receptor T-cell cancer therapies. This partnership connects Immatics' skills in discovering and making TCR therapy with BMS's success in marketing and developing cancer treatments.
• In September 2023, Roche Diagnostics introduced the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay to personalised cancer care. It needs the FOLR1 companion diagnostic as an immunohistochemistry (IHC) test to show if ovarian cancer cells have folate receptor alpha (FOLR1) activity.
• In April 2023, Merck made public its plans to purchase Prometheus Biosciences for around USD 10.8 billion to obtain Prometheus's lead drug MK-7240, previously known as PRA023. Medical research shows that this specific monoclonal antibody targeting TL1A provides good results for treating inflammatory bowel diseases, particularly ulcerative colitis and Crohn's disease. The acquisition helps Merck establish a stronger role in immunology along with enhancing its non-oncology drug development projects.